As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.
8 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:
8 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:
| Dec '24 |
+/-
%
|
||
| Revenue | 1.52 1.52 |
7,500%
7,500%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
|
| EBIT (Operating Income) EBIT | -19 -19 |
55%
55%
|
|
| Net Profit | -18 -18 |
81%
81%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
| Head office | Australia |
| CEO | John Friend |
| Employees | 13 |
| Founded | 1994 |
| Website | www.kaziatherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


